-
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration
Gelissen, L. M. Y., Loveless, S., Toorop, A. A., Howlett, J., Loeff, F. C., Rispens, T., Killestein, J., Tallantyre, E. C. & van Kempen, Z. L. E., 1 Oct 2024, In: Multiple Sclerosis and Related Disorders. 90, 105796.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial
Toorop, A. A., Wessels, M. H. J., Gelissen, L. M. Y., Hoitsma, E., Zeinstra, E. M. P. E., van Rooij, L. C., van Munster, C. E. P., Vennegoor, A., Mostert, J. P., Wokke, B. H. A., Kalkers, N. F., Hoogervorst, E. L. J., van Eijk, J. J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L. G. F., Kloosterziel, M. E., & 11 others, 15 Jul 2024, In: Journal of the neurological sciences. 462, p. 123102 123102.Research output: Contribution to journal › Article › Academic › peer-review
-
Treatment with natalizumab and ocrelizumab in multiple sclerosis: The road towards a personalized approach
Toorop, A. A., 24 Nov 2023, 279 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal
- All publications
